Experiences of Rare Diseases: an Insight from Patients and Families

Total Page:16

File Type:pdf, Size:1020Kb

Experiences of Rare Diseases: an Insight from Patients and Families Experiences of Rare Diseases: An Insight from Patients and Families Unit 4D, Leroy House 436 Essex Road London N1 3QP tel: 02077043141 fax: 02073591447 [email protected] www.raredisease.org.uk By Lauren Limb, Stephen Nutt and Alev Sen - December 2010 Web and press design www.raredisease.org.uk WordsAndPeople.com About Rare Disease UK Rare Disease UK (RDUK) is the national alliance for people with rare diseases and all who support them. Our membership is open to all and includes patient organisations, clinicians, researchers, academics, industry and individuals with an interest in rare diseases. RDUK was established by Genetic RDUK is campaigning for a Alliance UK, the national charity strategy for integrated service of over 130 patient organisations delivery for rare diseases. This supporting all those affected by would coordinate: genetic conditions, in conjunction with other key stakeholders | Research in November 2008 following the European Commission’s | Prevention and diagnosis Communication on Rare Diseases: | Treatment and care Europe’s Challenges. | Information Subsequently RDUK successfully | Commissioning and planning campaigned for the adoption of the Council of the European into one cohesive strategy for all Union’s Recommendation on patients affected by rare disease in an action in the field of rare the UK. As well as securing better diseases. The Recommendation outcomes for patients, a strategy was adopted unanimously by each would enable the most effective Member State of the EU (including use of NHS resources. the UK) in June 2009. The Recommendation calls on Member States to adopt plans or strategies for rare diseases by 2013. Contents Chair’s Foreword ........................................................................................................................2 Introduction ................................................................................................................................3 Summary of Key Findings ...........................................................................................................................4 Research .......................................................................................................................................5 Carl Tilson’s story.......................................................................................................................7 Diagnosis .....................................................................................................................................8 Jayne Hughes’ story .................................................................................................................12 Anna Pickering’s story..............................................................................................................13 Jo Grey’s story .........................................................................................................................14 Patient Care, Information and Support ...................................................................................15 Anne Begg MP’s story .............................................................................................................18 Rhya Homewood’s story ..........................................................................................................19 Fiona Fisher’s story...................................................................................................................20 Coordination of Care ................................................................................................................21 Kay Parkinson’s story ...............................................................................................................25 Craig and Gemma Mitchell’s story ...........................................................................................26 Toby Mildon’s story .................................................................................................................27 Charles and Miranda’s story.....................................................................................................28 Access to treatment ..................................................................................................................29 Gillian Thomas’ story ...............................................................................................................31 Annex 1: List of conditions represented in the survey ..........................................................32 Experiences of Rare Diseases: An Insight from Patients and Families and Patients from Insight An Diseases: Rare of Experiences Rare Disease UK (RDUK) | 1 Chair’s Foreword Advances in scientific research over the last two decades have highlighted the emerging possibility of addressing the needs of patients and families with rare genetic disorders in ways that would have been dismissed as science fiction only a few years ago. This gives rise to great optimism about the future. However, future possibilities must not blind us to the situation of patients and families struggling with the daily reality of life with a rare disease today. This survey, reporting the The evidence reported in the experiences of nearly 600 pages that follow highlight families with rare diseases across the need to act now to bring the UK, is one of the largest services and support together that has ever been carried out. in a strategic, coherent plan to The picture it paints is a bleak utilise knowledge and resources one, with significant numbers effectively and in so doing, reporting delays in diagnosis. produce the best possible benefits Wrong diagnoses are common for patients and families given (sometimes happening two, three current scientific understanding of or more times). Access to specialist good clinical practice, delivered in knowledge and expertise is too a timely, user-friendly way. often fraught with difficulties and unnecessary institutional obstacles get in the way for patients and families seeking the help and support they need and should be able to expect. Alastair Kent Chair of Rare Disease UK Director of Genetic Alliance UK Experiences of Rare Diseases: An Insight from Patients and Families and Patients from Insight An Diseases: Rare of Experiences 2 | Rare Disease UK (RDUK) Introduction Over the summer of 2010, Rare Disease UK (RDUK) carried out a survey of patients and families affected by rare diseases. The aim of this survey was to find out more about the experiences of people living with a rare condition in the UK, and to identify some of the common issues and problems they frequently face. At RDUK, we are too Of the 570 valid responses, 47% in Wales and 3% in Northern often told of the were from the patient themselves, Ireland. The remaining 1% of 49% were from a carer or family responses were patients living in difficulties patients with member of someone with a the Channel Islands. This is broadly rare diseases experience rare disease, and the remaining representative of the population in getting a diagnosis and 4% were from other interested of the UK as a whole and as such accessing appropriate parties which included healthcare demonstrates that we are able services, information professionals responding on to suggest that our findings are behalf of a patient, and carriers of a good representation of the and support throughout a rare disease. general situation in the UK. the progression of their condition. We A total of 119 different rare The results support the need for a therefore felt that it was conditions are represented in national strategy for rare diseases important to conduct a the survey. A full list of these in the UK and complements conditions can be seen in Annex RDUK’s work in investigating survey to gain a better 1. These conditions ranged from what should form the basis of understanding of these ultra-rare to the more “common” a strategy. We believe that a issues and to better rare diseases and included national strategy would reduce understand the scale of chromosomal, single gene, the fragmentation of services the problem. multifactorial and non-genetic and ensure that patients of rare conditions, as well as undiagnosed conditions are able to access The survey covered multiple conditions, “The survey also equitable, high and patients quality care, aspects of rare diseases which highlights inequalities in our members have informed us who suffered information and they experience problems with from multiple the services received by support in a timely different rare manner, whilst including, diagnosis, coordination patients with different of care, awareness and diseases. Despite at the same time participation in research, access the wide rare diseases and even making a more variation in efficient use of NHS to drugs and services, and access between those affected to thorough, reliable information the symptoms, resources. and support. prognoses by the same rare disease and medical Throughout this in different parts of the The online survey was sent out to needs of these publication we all of RDUK’s members, including conditions, the country” have included case patient organisations, many of survey indicated studies of a number which forwarded it to their own commonalities in experiences in of patients or families affected by members. Paper copies were regards to their care, information rare diseases to provide detail on available for those who requested and support. The survey also their experiences and to put some them. highlights inequalities in the of
Recommended publications
  • Inherited Neuropathies
    407 Inherited Neuropathies Vera Fridman, MD1 M. M. Reilly, MD, FRCP, FRCPI2 1 Department of Neurology, Neuromuscular Diagnostic Center, Address for correspondence Vera Fridman, MD, Neuromuscular Massachusetts General Hospital, Boston, Massachusetts Diagnostic Center, Massachusetts General Hospital, Boston, 2 MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology Massachusetts, 165 Cambridge St. Boston, MA 02114 and The National Hospital for Neurology and Neurosurgery, Queen (e-mail: [email protected]). Square, London, United Kingdom Semin Neurol 2015;35:407–423. Abstract Hereditary neuropathies (HNs) are among the most common inherited neurologic Keywords disorders and are diverse both clinically and genetically. Recent genetic advances have ► hereditary contributed to a rapid expansion of identifiable causes of HN and have broadened the neuropathy phenotypic spectrum associated with many of the causative mutations. The underlying ► Charcot-Marie-Tooth molecular pathways of disease have also been better delineated, leading to the promise disease for potential treatments. This chapter reviews the clinical and biological aspects of the ► hereditary sensory common causes of HN and addresses the challenges of approaching the diagnostic and motor workup of these conditions in a rapidly evolving genetic landscape. neuropathy ► hereditary sensory and autonomic neuropathy Hereditary neuropathies (HN) are among the most common Select forms of HN also involve cranial nerves and respiratory inherited neurologic diseases, with a prevalence of 1 in 2,500 function. Nevertheless, in the majority of patients with HN individuals.1,2 They encompass a clinically heterogeneous set there is no shortening of life expectancy. of disorders and vary greatly in severity, spanning a spectrum Historically, hereditary neuropathies have been classified from mildly symptomatic forms to those resulting in severe based on the primary site of nerve pathology (myelin vs.
    [Show full text]
  • Opsoclonus-Myoclonus Syndrome
    OMS Opsoclonus-Myoclonus Syndrome REGISTRY POWERED BY NORD 10 11 Tr io Health © 2019 Trio Health Advisory Group, Inc.; NORD - National Organization for Rare Disorders, Inc. | All rights reserved. © 2019 Trio Health Advisory Group, Inc.; NORD - National Organization for Rare Disorders, Inc. | All rights reserved. Tr io Health Meet OMS Warrior ALEXA What is OMS? OPSOCLONUS-MYOCLONUS SYNDROME General Discussion Opsoclonus-myoclonus syndrome (OMS) is an inflammatory neurological disorder, often occurring as a paraneoplastic syndrome with neurological symptoms being the first sign of an occult tumor. It is characterized by associated ocular, motor, behavioral, sleep, and language disturbances. The onset is oftentimes abrupt and can be relatively severe, with the potential to become chronic unless the appropriate diagnosis and treatment are reached in a timely manner. Signs and Symptoms The component features of OMS include the presence of rapid, seemingly random eye movements in the horizontal, vertical, and diagonal directions (opsoclonus); an unsteady gait or inability to walk or stand (ataxia); and brief, repetitive, shock-like muscle spasms or tremors within the arms, legs, or hands interfering with normal use (myoclonus). Behavioral and sleep disturbances, including extreme irritability, inconsolable crying, reduced or fragmented sleep (insomnia), and rage attacks are common. Difficulty articulating speech (dysarthria), sometimes with complete loss of speech and language, may occur. Additional symptoms, such as decreased muscle tone (hypotonia) and vomiting, have also been noted. Causes The most common cause of OMS in young children is an occult (ie, a small, often hidden) tumor. The symptoms of OMS, as a paraneoplastic syndrome, presumably stem from the immune system attacking the tumor, leading to secondary inflammatory effects on the central nervous system.
    [Show full text]
  • Neuromyotonia in Hereditary Motor Neuropathy J Neurol Neurosurg Psychiatry: First Published As 10.1136/Jnnp.54.3.230 on 1 March 1991
    230 Journal ofNeurology, Neurosurgery, and Psychiatry 1991;54:230-235 Neuromyotonia in hereditary motor neuropathy J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.54.3.230 on 1 March 1991. Downloaded from A F Hahn, A W Parkes, C F Bolton, S A Stewart Abstract Case II2 Two siblings with a distal motor This 15 year old boy had always been clumsy. neuropathy experienced cramping and Since the age of 10, he had noticed generalised difficulty in relaxing their muscles after muscle stiffness which increased with physical voluntary contraction. Electromyogra- activity such as walking upstairs, running and phic recordings at rest revealed skating. For some time, he was aware of repetitive high voltage spontaneous elec- difficulty in releasing his grip and his fingers trical discharges that were accentuated tended to cramp on writing. He had noticed after voluntary contraction and during involuntary twitching of his fingers, forearm ischaemia. Regional neuromuscular muscles and thighs at rest and it was more blockage with curare indicated hyperex- pronounced after a forceful voluntary con- citability of peripheral nerve fibres and traction. Muscle cramping and spontaneous nerve block suggested that the ectopic muscle activity were particularly unpleasant activity originated in proximal segments when he re-entered the house in the winter, of the nerve. Symptoms were improved for example, after a game of hockey. Since the with diphenylhydantoin, carbamazepine age of twelve, he had noticed a tendency to and tocainide. trip. Subsequently he developed bilateral foot drop and weakness of his hands. He denied sensory symptoms and perspired only with The term "neuromyotonia" was coined by exertion.
    [Show full text]
  • Diseases of the Digestive System (KOO-K93)
    CHAPTER XI Diseases of the digestive system (KOO-K93) Diseases of oral cavity, salivary glands and jaws (KOO-K14) lijell Diseases of pulp and periapical tissues 1m Dentofacial anomalies [including malocclusion] Excludes: hemifacial atrophy or hypertrophy (Q67.4) K07 .0 Major anomalies of jaw size Hyperplasia, hypoplasia: • mandibular • maxillary Macrognathism (mandibular)(maxillary) Micrognathism (mandibular)( maxillary) Excludes: acromegaly (E22.0) Robin's syndrome (087.07) K07 .1 Anomalies of jaw-cranial base relationship Asymmetry of jaw Prognathism (mandibular)( maxillary) Retrognathism (mandibular)(maxillary) K07.2 Anomalies of dental arch relationship Cross bite (anterior)(posterior) Dis to-occlusion Mesio-occlusion Midline deviation of dental arch Openbite (anterior )(posterior) Overbite (excessive): • deep • horizontal • vertical Overjet Posterior lingual occlusion of mandibular teeth 289 ICO-N A K07.3 Anomalies of tooth position Crowding Diastema Displacement of tooth or teeth Rotation Spacing, abnormal Transposition Impacted or embedded teeth with abnormal position of such teeth or adjacent teeth K07.4 Malocclusion, unspecified K07.5 Dentofacial functional abnormalities Abnormal jaw closure Malocclusion due to: • abnormal swallowing • mouth breathing • tongue, lip or finger habits K07.6 Temporomandibular joint disorders Costen's complex or syndrome Derangement of temporomandibular joint Snapping jaw Temporomandibular joint-pain-dysfunction syndrome Excludes: current temporomandibular joint: • dislocation (S03.0) • strain (S03.4) K07.8 Other dentofacial anomalies K07.9 Dentofacial anomaly, unspecified 1m Stomatitis and related lesions K12.0 Recurrent oral aphthae Aphthous stomatitis (major)(minor) Bednar's aphthae Periadenitis mucosa necrotica recurrens Recurrent aphthous ulcer Stomatitis herpetiformis 290 DISEASES OF THE DIGESTIVE SYSTEM Diseases of oesophagus, stomach and duodenum (K20-K31) Ill Oesophagitis Abscess of oesophagus Oesophagitis: • NOS • chemical • peptic Use additional external cause code (Chapter XX), if desired, to identify cause.
    [Show full text]
  • Prevalence and Incidence of Rare Diseases: Bibliographic Data
    Number 1 | January 2019 Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order) www.orpha.net www.orphadata.org If a range of national data is available, the average is Methodology calculated to estimate the worldwide or European prevalence or incidence. When a range of data sources is available, the most Orphanet carries out a systematic survey of literature in recent data source that meets a certain number of quality order to estimate the prevalence and incidence of rare criteria is favoured (registries, meta-analyses, diseases. This study aims to collect new data regarding population-based studies, large cohorts studies). point prevalence, birth prevalence and incidence, and to update already published data according to new For congenital diseases, the prevalence is estimated, so scientific studies or other available data. that: Prevalence = birth prevalence x (patient life This data is presented in the following reports published expectancy/general population life expectancy). biannually: When only incidence data is documented, the prevalence is estimated when possible, so that : • Prevalence, incidence or number of published cases listed by diseases (in alphabetical order); Prevalence = incidence x disease mean duration. • Diseases listed by decreasing prevalence, incidence When neither prevalence nor incidence data is available, or number of published cases; which is the case for very rare diseases, the number of cases or families documented in the medical literature is Data collection provided. A number of different sources are used : Limitations of the study • Registries (RARECARE, EUROCAT, etc) ; The prevalence and incidence data presented in this report are only estimations and cannot be considered to • National/international health institutes and agencies be absolutely correct.
    [Show full text]
  • Connexin29 Is Uniquely Distributed Within Myelinating Glial Cells of the Central and Peripheral Nervous Systems
    The Journal of Neuroscience, August 1, 2002, 22(15):6458–6470 Connexin29 Is Uniquely Distributed within Myelinating Glial Cells of the Central and Peripheral Nervous Systems Bruce M. Altevogt,2* Kleopas A. Kleopa,3* Friso R. Postma,1 Steven S. Scherer,3 and David L. Paul1 1Department of Neurobiology and 2Program in Neuroscience, Harvard Medical School, Boston, Massachusetts 02115, and 3Department of Neurology, The University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104-6077 Although both Schwann cells and oligodendrocytes express lower levels than Cx32 in adulthood. In adult sciatic nerve, connexin32 (Cx32), the loss of this connexin causes demyeli- Cx29 was primarily localized to the innermost aspects of the nation only in the PNS. To determine whether oligodendrocytes myelin sheath, the paranode, the juxtaparanode, and the inner might express another connexin that can function in place of mesaxon. Cx29 displayed a striking coincidence with Kv1.2 K ϩ Cx32, we searched for novel CNS-specific connexins using channels, which are localized in the axonal membrane. Both reverse transcriptase-PCR and degenerate primers. We identi- Cx29 and Cx32 were found in the incisures. Cx29 expressed in fied Cx29, whose transcript was restricted to brain, spinal cord, N2A cells did not induce intercellular conductances but did and sciatic nerve. Developmental expression of Cx29 mRNA in participate in the formation of active channels when coex- the CNS paralleled that of other myelin-related mRNAs, includ- pressed with Cx32. Together, these data show that Cx29 and ing Cx32. In the CNS, Cx29 antibodies labeled the internodal Cx32 are expressed by myelinating glial cells with distinct and juxtaparanodal regions of small myelin sheaths, whereas distributions.
    [Show full text]
  • Insurance and Advance Pay Test Requisition
    Insurance and Advance Pay Test Requisition (2021) For Specimen Collection Service, Please Fax this Test Requisition to 1.610.271.6085 Client Services is available Monday through Friday from 8:30 AM to 9:00 PM EST at 1.800.394.4493, option 2 Patient Information Patient Name Patient ID# (if available) Date of Birth Sex designated at birth: 9 Male 9 Female Street address City, State, Zip Mobile phone #1 Other Phone #2 Patient email Language spoken if other than English Test and Specimen Information Consult test list for test code and name Test Code: Test Name: Test Code: Test Name: 9 Check if more than 2 tests are ordered. Additional tests should be checked off within the test list ICD-10 Codes (required for billing insurance): Clinical diagnosis: Age at Initial Presentation: Ancestral Background (check all that apply): 9 African 9 Asian: East 9 Asian: Southeast 9 Central/South American 9 Hispanic 9 Native American 9 Ashkenazi Jewish 9 Asian: Indian 9 Caribbean 9 European 9 Middle Eastern 9 Pacific Islander Other: Indications for genetic testing (please check one): 9 Diagnostic (symptomatic) 9 Predictive (asymptomatic) 9 Prenatal* 9 Carrier 9 Family testing/single site Relationship to Proband: If performed at Athena, provide relative’s accession # . If performed at another lab, a copy of the relative’s report is required. Please attach detailed medical records and family history information Specimen Type: Date sample obtained: __________ /__________ /__________ 9 Whole Blood 9 Serum 9 CSF 9 Muscle 9 CVS: Cultured 9 Amniotic Fluid: Cultured 9 Saliva (Not available for all tests) 9 DNA** - tissue source: Concentration ug/ml Was DNA extracted at a CLIA-certified laboratory or a laboratory meeting equivalent requirements (as determined by CAP and/or CMS)? 9 Yes 9 No 9 Other*: If not collected same day as shipped, how was sample stored? 9 Room temp 9 Refrigerated 9 Frozen (-20) 9 Frozen (-80) History of blood transfusion? 9 Yes 9 No Most recent transfusion: __________ /__________ /__________ *Please contact us at 1.800.394.4493, option 2 prior to sending specimens.
    [Show full text]
  • Psykisk Utviklingshemming Og Forsinket Utvikling
    Psykisk utviklingshemming og forsinket utvikling Genpanel, versjon v03 Tabellen er sortert på gennavn (HGNC gensymbol) Navn på gen er iht. HGNC >x10 Andel av genet som har blitt lest med tilfredstillende kvalitet flere enn 10 ganger under sekvensering x10 er forventet dekning; faktisk dekning vil variere. Gen Gen (HGNC Transkript >10x Fenotype (symbol) ID) AAAS 13666 NM_015665.5 100% Achalasia-addisonianism-alacrimia syndrome OMIM AARS 20 NM_001605.2 100% Charcot-Marie-Tooth disease, axonal, type 2N OMIM Epileptic encephalopathy, early infantile, 29 OMIM AASS 17366 NM_005763.3 100% Hyperlysinemia OMIM Saccharopinuria OMIM ABCB11 42 NM_003742.2 100% Cholestasis, benign recurrent intrahepatic, 2 OMIM Cholestasis, progressive familial intrahepatic 2 OMIM ABCB7 48 NM_004299.5 100% Anemia, sideroblastic, with ataxia OMIM ABCC6 57 NM_001171.5 93% Arterial calcification, generalized, of infancy, 2 OMIM Pseudoxanthoma elasticum OMIM Pseudoxanthoma elasticum, forme fruste OMIM ABCC9 60 NM_005691.3 100% Hypertrichotic osteochondrodysplasia OMIM ABCD1 61 NM_000033.3 77% Adrenoleukodystrophy OMIM Adrenomyeloneuropathy, adult OMIM ABCD4 68 NM_005050.3 100% Methylmalonic aciduria and homocystinuria, cblJ type OMIM ABHD5 21396 NM_016006.4 100% Chanarin-Dorfman syndrome OMIM ACAD9 21497 NM_014049.4 99% Mitochondrial complex I deficiency due to ACAD9 deficiency OMIM ACADM 89 NM_000016.5 100% Acyl-CoA dehydrogenase, medium chain, deficiency of OMIM ACADS 90 NM_000017.3 100% Acyl-CoA dehydrogenase, short-chain, deficiency of OMIM ACADVL 92 NM_000018.3 100% VLCAD
    [Show full text]
  • Prolonged Sinus Pauses Revealing a Paroxysmal Extreme Pain Disorder: Is It a Frequent Situation? Case Report
    iMedPub Journals INTERNATIONAL ARCHIVES OF MEDICINE 2015 http://journals.imed.pub SECTION: PEDIATRICS Vol. 8 No. 228 ISSN: 1755-7682 doi: 10.3823/1827 Prolonged Sinus Pauses Revealing a Paroxysmal Extreme Pain Disorder: Is it a Frequent Situation? CASE REPORT Sahar Mouram1, Abstract Hicham Sabor2, Ibtissam Fellat1 Title: Paroxysmal extreme pain disorder (PEPD) is an autosomal do- minant painful neuropathy with many, but not all, cases linked to 1 Cardiology B Department, Faculty gain-of-function mutations in SCN9A which encodes voltage-gated of Medicine and Pharmacy, Rabat, sodium channel Na. 1.7. It is a very rare condition featured by flushing Morocco. of the lower half of the body and excruciating burning pain caused 2 Cardiology Department, Military Hospital, Faculty of Medicine and by any stimulus below the waist or in the perianal region. PEPD may Pharmacy, Rabat, Morocco. be associated with cardiovascular instability, especially prolonged sinus pauses, and thus has anesthetic implications. Pacemaker implantation Contact information: is the alternative therapeutic option, but its indications have not been clarified yet. Sahar Mouram. Cardiology B Department. Background: This condition is well described in neurological litera- Address: Faculty of Medicine and ture, but to our knowledge, this is the first case report of a patient Pharmacy, Rabat, Morocco. with paroxysmal extreme pain disorder with prolonged sinus pauses Tel: 00212(0)661630785. requiring anesthesia for an epicardial pacemaker even with the peri- operative risk of the pathology. This clinical observation can help for [email protected] a better management and understanding of the cardiac risk compli- cations of PEPD especially for an infant whose diagnostic is frequently made at the stage of complication This clinical observation can put the item on the necessity of establishing recommendations for mana- gement of cardiac complications during PEPD.
    [Show full text]
  • Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
    fphar-07-00121 May 7, 2016 Time: 11:45 # 1 REVIEW published: 10 May 2016 doi: 10.3389/fphar.2016.00121 Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery Paola Imbrici1*, Antonella Liantonio1, Giulia M. Camerino1, Michela De Bellis1, Claudia Camerino2, Antonietta Mele1, Arcangela Giustino3, Sabata Pierno1, Annamaria De Luca1, Domenico Tricarico1, Jean-Francois Desaphy3 and Diana Conte1 1 Department of Pharmacy – Drug Sciences, University of Bari “Aldo Moro”, Bari, Italy, 2 Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari “Aldo Moro”, Bari, Italy, 3 Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro”, Bari, Italy In the human genome more than 400 genes encode ion channels, which are transmembrane proteins mediating ion fluxes across membranes. Being expressed in all cell types, they are involved in almost all physiological processes, including sense perception, neurotransmission, muscle contraction, secretion, immune response, cell proliferation, and differentiation. Due to the widespread tissue distribution of ion channels and their physiological functions, mutations in genes encoding ion channel subunits, or their interacting proteins, are responsible for inherited ion channelopathies. These diseases can range from common to very rare disorders and their severity can be mild, Edited by: disabling, or life-threatening. In spite of this, ion channels are the primary target of only Maria Cristina D’Adamo, University of Perugia, Italy about 5% of the marketed drugs suggesting their potential in drug discovery. The current Reviewed by: review summarizes the therapeutic management of the principal ion channelopathies Mirko Baruscotti, of central and peripheral nervous system, heart, kidney, bone, skeletal muscle and University of Milano, Italy Adrien Moreau, pancreas, resulting from mutations in calcium, sodium, potassium, and chloride ion Institut Neuromyogene – École channels.
    [Show full text]
  • Isaacs' Syndrome (Autoimmune Neuromyotonia) in a Patient with Systemic Lupus Erythematosus
    Case Report Isaacs’ Syndrome (Autoimmune Neuromyotonia) in a Patient with Systemic Lupus Erythematosus PHILIP W. TAYLOR ABSTRACT. Patients with systemic lupus erythematosus (SLE) often produce autoantibodies against a large num- ber of antigens. A case of SLE is presented in which muscle twitching and muscle cramps were asso- ciated with an autoantibody directed against the voltage-gated potassium channel of peripheral nerves (Isaacs’ syndrome). (J Rheumatol 2005;32:757–8) Key Indexing Terms: SYSTEMIC LUPUS ERYTHEMATOSUS AUTOIMMUNE NEUROMYOTONIA ISAACS’ SYNDROME CHANNELOPATHY Systemic lupus erythematosus (SLE) is a multi-system ill- trunk and abdominal muscles, muscles in the arms, and rarely the muscles ness characterized by autoantibody production and inflam- of the face. The muscle twitching was worse with exertion and was associ- matory damage to tissues and organ systems. Neuro- ated with cramping in the arm and leg muscles. There was no muscle weakness on examination. Diffuse continuous muscular symptoms may be the result of inflammatory fasciculations were observed in the muscles of the legs, particularly in the myopathy or peripheral neuropathy. Inflammatory myopa- calf. Mental status, cranial nerves, reflexes, and sensory examination were thy may be discovered by electromyography (EMG) and all normal. Sodium, potassium, calcium, magnesium, creatine phosphoki- muscle biopsy. Peripheral neuropathy is diagnosed by nerve nase, parathyroid hormone, liver function tests, and thyroid function tests conduction studies and sural nerve biopsy. were all normal. Single motor unit discharges in doublets, triplets, and occasional quadruplets were observed by EMG examination of muscles of The SLE patient in this case report developed muscle the upper and lower extremities, most prominently in the gastrocnemius twitching and muscle cramps.
    [Show full text]
  • Tests Performed Through Our International Collaboration
    Tests performed through our international collaboration Molecular Studies for Inborn Errors of Metabolism A Inborn Errors of Metabolism Defective Gene 1 Acyl - Co A oxidase deficiency ACOX 1 2 Argininosuccinate lyase deficiency ASL 3 Aromatic L – amino acid decarboxylase (AADC) DDC Deficiency 4 Carnitine – acylcarnitine translocase (CACT) CACT Deficiency 5 Primary (systemic) carnitine deficiency OCTN2 6 Carnitine palmitoyltransferase I (CPT1) CPT1A 7 Carnitine palmitoyltransferase 2 (CPT2) CPT2 8 CHILD Syndrome NSDHL 9 Conradi – Hunermann – Happle syndrome EBP (CDPX2) 10 D – Bifunctional protein (DBP) Deficiency DBP, MFE2 11 Desmosterolosis DHCR24 12 Dihydropyrimidinase (DHP) Deficiency DPYS 13 Dihydropyrimidine dehydrogenase (DPD) DPYD Deficiency 14 Ethylmalonaciduria ETHE1 (Ethylmalonic encephalopathy) 15 Fructose intolerance, hereditary ALDOB 16 Galactosemia, classic GALT 17 Galactokinase deficiency GALK1 18 Glutaric aciduria type I (Glutaryl – Co A GCDH dehydrogenase deficiency 19 Glycogen storage disease 0 GYS2 20 Greenberg skeletal dysplasia LBR (Sterol – delta 14 reductase deficiency) 21 GTP cyclohydrolase I deficiency GCH1 22 Hydroxyacyl – Co A dehydrogenase deficiency HADH2 (2 – Methyl – 3 – hydroxybutyryl – CoA dehydrogenase deficiency) 23 Hyper Ig D Syndrome MVK (Mevalonate Kinase deficiency) 24 Hyperoxaluria type I AGXT 25 Isovaleric acidemia IVD 26 Lathosterolosis SC5DL 27 3 – methylglutaconicaciduria type I (3 – AUH methylglutaconyl – CoA hydratase deficiency) 28 Medium – chain – acyl – Co A dehydrogenase ACADM (MCAD) Deficiency
    [Show full text]